Characterizing the protein-protein interaction between MDM2 and 14-3-3σ; proof of concept for small molecule

Jake A Ward1, Beatriz Romartinez-Alonso2, Danielle F Kay3

  • 1Leicester Institute for Structural and Chemical Biology, University of Leicester, Leicester, UK; Mechanisms of Cancer and Aging Laboratory, Department of Molecular and Cell Biology, University of Leicester, Leicester, UK.

PubMed

Insights

Stabilizing the 14-3-3σ/MDM2 interaction with small molecules offers a cancer therapy strategy. Di-phosphorylation of MDM2 at S166/S186 is key for this interaction, which can be enhanced by fusicoccin A.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Cancer Therapeutics

Background:

  • Mouse Double Minute 2 (MDM2) inhibits the tumor suppressor p53 and is overexpressed in many cancers.
  • The 14-3-3σ protein regulates MDM2 localization and stability, making the 14-3-3σ/MDM2 interaction a therapeutic target.
  • Stabilizing this protein-protein interaction (PPI) with small molecules is a potential anti-cancer strategy.

Purpose of the Study:

  • To characterize the biophysical and structural basis of the interaction between 14-3-3σ and MDM2.
  • To investigate the role of MDM2 phosphorylation in this interaction.
  • To explore the potential of small molecules in stabilizing the 14-3-3σ/MDM2 PPI for cancer treatment.

Main Methods:

  • Detailed biophysical and structural characterization of 14-3-3σ and MDM2 peptides.
  • Analysis of phosphorylation-dependent binding using structural and biochemical techniques.
  • Investigation of small molecule (fusicoccin A) effects on the PPI.

Main Results:

  • Di-phosphorylation of MDM2 at S166 and S186 is essential for high-affinity binding to 14-3-3σ.
  • The MDM2 peptide binds to a 14-3-3σ dimer, with phosphorylation sites rocking between binding grooves.
  • Fusicoccin A stabilizes the 14-3-3σ/MDM2 PPI by forming a ternary complex.

Conclusions:

  • The phosphorylation-dependent 14-3-3σ/MDM2 interaction is structurally unique and druggable.
  • Small molecule stabilization of this PPI is a viable therapeutic strategy for cancer.
  • This study provides a foundation for developing novel small molecule stabilizers targeting the 14-3-3σ/MDM2 interaction.